Lv1
35 积分 2021-02-22 加入
Twenty-four-week anti-PD-1 antibody regimen promoted HBsAg reduction and concurrently enhanced HBV-specific T cell responses in patients with chronic hepatitis B
16天前
已完结
A new class of mRNA drugs targets poison exons
26天前
已完结
Progress and Future Directions in Exon Skipping and Inclusion Therapies: The Landscape of Oligonucleotide-Based Genetic Medicine
26天前
已完结
Artificial intelligence in drug discovery — what it is, where we stand and the path forward
1个月前
已完结
The Next Generation of Antibody Drug Conjugates
1个月前
已完结
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia
3个月前
已完结
Migraine
3个月前
已完结
Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine
3个月前
已完结
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
3个月前
已完结
Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine
4个月前
已完结
皖公网安备34019202002308
